Dr. Reddy’s Laboratories Limited
Pharmaceuticals
Annual Returns


Cumulative Returns and Drawdowns


Ownership

Margined

AI Summary
asof: 2026-09-14
Headwinds and Challenges
- The rituximab biosimilar approval is for the U.S. market, but
Dr. Reddy’s will not commercialize the product there itself. Under a
commercialization agreement, Fresenius Kabi holds the exclusive rights
to commercialize the product in the United States. This means
Dr. Reddy’s participation in the U.S. commercial opportunity is through
a partner rather than directly.
- The U.S. rituximab biosimilar market is described as one of the
world’s most important pharmaceutical markets, but the announcement does
not quantify the expected revenue or margin contribution to
Dr. Reddy’s.
- The company’s broader biosimilars business is still described as
being in a build-out phase, with several pipeline products in oncology
and autoimmune diseases at various stages of development for global
launches, and with manufacturing capacity being ramped up to support
global expansion plans. This indicates ongoing investment and execution
requirements.
- The forward-looking disclaimer in the press release identifies a
wide range of risks and uncertainties that could cause actual results to
differ materially from expectations, including general economic
conditions, competition, regulatory changes, and the impact of
acquisitions or reorganization.
Tailwinds and Growth Prospects
- On August 1, 2026, Dr. Reddy’s announced that the U.S. FDA approved
its rituximab biosimilar, a biosimilar to Rituxan® (rituximab), for the
U.S. market. The approval strengthens the company’s growing global
biosimilars portfolio and advances its biosimilars business in the
United States.
- The product was developed, manufactured and submitted for approval
by Dr. Reddy’s. The approval followed a successful recent Pre-License
Inspection (PLI) by the U.S. FDA at the company’s biologics
manufacturing facility in Bachupally, Hyderabad. This reflects the
company’s capabilities in bringing complex biologic medicines to highly
regulated markets.
- The rituximab biosimilar has already been commercialized in India,
the European Union, the United Kingdom and more than 25 emerging
markets, and has received marketing approval in Switzerland and Canada.
This provides a track record of regulatory approvals and commercial
presence across multiple geographies.
- The company’s Biologics team has over 25 years of development into a
fully integrated organization with capabilities in development,
manufacture and commercialization of biosimilars in oncology and
immunology. It has a current portfolio of six commercial products
marketed in India, with some products marketed in more than 30 other
countries.
- In 2024, Dr. Reddy’s launched its first biosimilar in the United
Kingdom, Versavo® (biosimilar bevacizumab). This followed the launch of
pegfilgrastim in the U.S. and Europe through a partner. The company also
launched its rituximab biosimilar in Europe in 2025. The biosimilars
business is described as having a key role in driving both near-term and
long-term growth.
- The company is ramping up manufacturing capacity to support global
expansion plans, and has several pipeline products in oncology and
autoimmune diseases in various stages of development for global launches
across developed and emerging markets.
Key Risks
- The press release includes a forward-looking statement disclaimer
noting known and unknown risks and uncertainties that could cause actual
results, performance or events to differ materially from those expressed
or implied. These include general economic conditions, performance of
financial markets, credit defaults, currency exchange rates, interest
rates, mortality and morbidity levels and trends, changing levels of
competition, changes in laws and regulations and in the policies of
central banks and/or governments, the impact of acquisitions or
reorganization including related integration issues, and the
susceptibility of the industry and markets to economic downturns as a
result of natural disasters, epidemics, pandemics or other widespread
illness, including coronavirus (COVID-19).
- Additional risks and uncertainties are identified in the company’s
public filings with the Securities and Exchange Commission, including
those listed under the “Risk Factors” and “Forward-Looking Statements”
sections of the Annual Report on Form 20-F for the year ended March 31,
2026.
- The company assumes no obligation to update any information
contained in the press release.
Broker Narrative
The broker narrative evolved from 2023 concerns over gRevlimid-driven
US revenue declines, base-margin misses, domestic Covid-base drags, US
pricing and regulatory risk, and Russia/EM weakness toward a 2026 focus
on NRT integration costs, Semaglutide relaunch delays, PSAI and NRT
revenue declines, and forex volatility, while balance-sheet strength and
launch-pipeline optimism gave way to margin recovery via lower R&D
and overheads plus biosimilar approvals. Persistent themes include
gRevlimid-related US revenue pressure and generic price erosion, now
extended to Europe, alongside forex headwinds; resolved themes include
the acute Russia slump and domestic Covid-base distortion, which later
turned into 15% Russia growth and 17% domestic formulation growth.
Fears that came true
- The early warning of lower gRevlimid-driven US revenues
materialized, as the final report cites a YoY US revenue decline due to
the high base of gRevlimid, a backdrop associated with multiple
DISAPPOINTMENT outcomes and negative actual returns in the history.
- US pricing pressure flagged at the outset persisted into generic
price erosion in Europe and NRT revenue declines from higher distributor
rebates, recurring in periods marked by DISAPPOINTMENT-rated calls and
weak actual returns.
- Forex volatility cautioned in early Russia/EM weakness resurfaced in
the last report as a drag on other income, corresponding to flat or
negative actual returns in several later reports.
Optimism that failed
- The early expectation of ongoing meaningful gRevlimid earnings
support through FY23–25E failed to sustain, as the latest report treats
gRevlimid as a high base causing US revenue decline rather than a
continued earnings cushion.
Broker Timeline
67 broker calls · 2023-05-10 to 2026-10-26
CNBC-TV18: ratings, targets and commentary
No recorded CNBC-TV18 statements for this ticker.
Management comments
No recorded management comments with an explicit designation and affiliation for this ticker.
Copyright © 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.
🐞